Drugs Made In America Acquisition IIDMII 15 Earnings per Share (Diluted) is $0.23 as of Mar. 2026. GuruFocus rates DMII with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 172 Diversified Financial Services companies, Drugs Made In America Acquisition II ranks worse than 581394.77% on this metric.
Drugs Made In America Acquisition II (NAS:DMII) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Drugs Made In America Acquisition II Earnings per Share (Diluted) Related Terms
Drugs Made In America Acquisition II Earnings per Share (Diluted) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Drugs Made In America Acquisition II Earnings per Share (Diluted) Chart
Drugs Made In America Acquisition II Annual Data
Trend
Dec24
Dec25
Earnings per Share (Diluted)
0.00
0.15
Drugs Made In America Acquisition II Quarterly Data
DMII vs BCSS, EVAC, CEPF: Earnings per Share (Diluted) Comparison
For the Shell Companies subindustry, Drugs Made In America Acquisition II's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Drugs Made In America Acquisition II PE Ratio vs Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, Drugs Made In America Acquisition II's PE Ratio distribution charts can be found below:
* The bar in red indicates where Drugs Made In America Acquisition II's PE Ratio falls into.
Drugs Made In America Acquisition II Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.23
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $0.23 mean?
Drugs Made In America Acquisition II (DMII) has a Earnings per Share (Diluted) of $0.23 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Drugs Made In America Acquisition II and its competitors. According to the industry distribution chart, Drugs Made In America Acquisition II ranks #999999 out of 172 companies in the Diversified Financial Services industry.
Is Drugs Made In America Acquisition II's Earnings per Share (Diluted) too high?
Drugs Made In America Acquisition II's current Earnings per Share (Diluted) is $0.23. The Diversified Financial Services industry median Earnings per Share (Diluted) is 18.40. Drugs Made In America Acquisition II's value of $0.23 is 98.8% below this industry median. Based on the distribution chart, Drugs Made In America Acquisition II ranks #999999 out of 172 companies in the Diversified Financial Services industry, which is in the bottom quartile relative to peers. Overall, Drugs Made In America Acquisition II has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Drugs Made In America Acquisition II's Earnings per Share (Diluted) compare to BCSS and EVAC?
According to the Diversified Financial Services industry distribution chart, Drugs Made In America Acquisition II ranks #999999 out of 172 companies for Earnings per Share (Diluted). This places Drugs Made In America Acquisition II in the lower half of its industry. The industry median Earnings per Share (Diluted) is 18.40. Drugs Made In America Acquisition II's value of $0.23 is 98.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Diversified Financial Services company?
The median Earnings per Share (Diluted) among Diversified Financial Services companies is 18.40, based on 172 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Drugs Made In America Acquisition II's current Earnings per Share (Diluted) of $0.23 is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Drugs Made In America Acquisition II and its competitors. For the Diversified Financial Services industry, the median Earnings per Share (Diluted) is 18.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Drugs Made In America Acquisition II's current Earnings per Share (Diluted) is $0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drugs Made In America Acquisition II stock overvalued right now?
Drugs Made In America Acquisition II (DMII) has a current Earnings per Share (Diluted) of $0.23. The current Earnings per Share (Diluted) is $0.23 and 98.8% below the Diversified Financial Services industry median of 18.40. Drugs Made In America Acquisition II's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Drugs Made In America Acquisition II (DMII), the current Earnings per Share (Diluted) is $0.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Drugs Made In America Acquisition II Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMII has been successfully added to your 